Loading
A phase 3 trial of Trastuzumab deruxtecan, Pembrolizumab and Trastuzumab in gastric & gastro-oesophageal junction cancer, run by Daiichi Sankyo, now recruiting.
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer is a phase 3 interventional study registered as NCT06731478 by Daiichi Sankyo, with 726 participants planned, started 2025-02-27 and due to reach its primary completion in 2028-06-01. Interventions recorded: Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab and Chemotherapy.
Shares HER2-positive gastric cancer, Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan, Trastuzumab and the tag pipeline.
Shares HER2-positive gastric cancer, Daiichi Sankyo, Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Trastuzumab deruxtecan, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies and the tag pipeline.
Shares Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads), Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Trastuzumab, Monoclonal antibodies, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC), Pembrolizumab and the tag pipeline.